Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation

Abstract This research aims to create dabrafenib (DBF)-loaded nanosponges (NSPs) using β-cyclodextrin (β-CD) and diphenyl carbonate (DPC) as linker to improve oral bioavailability. DBF-loaded β-CD NSPs were synthesized by finely adjusting the molar ratio of β-CD to DPC and optimizing the stirring ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Konda Sri Chaya Reddy, Darna Bhikshapathi, Jaini Pavan Kumar
Format: Article
Language:English
Published: Universidade de São Paulo 2025-01-01
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100322&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832592485243682816
author Konda Sri Chaya Reddy
Darna Bhikshapathi
Jaini Pavan Kumar
author_facet Konda Sri Chaya Reddy
Darna Bhikshapathi
Jaini Pavan Kumar
author_sort Konda Sri Chaya Reddy
collection DOAJ
description Abstract This research aims to create dabrafenib (DBF)-loaded nanosponges (NSPs) using β-cyclodextrin (β-CD) and diphenyl carbonate (DPC) as linker to improve oral bioavailability. DBF-loaded β-CD NSPs were synthesized by finely adjusting the molar ratio of β-CD to DPC and optimizing the stirring rate and duration using design methodology. After being loaded with DBF, the produced β-CD NSPs were characterized in terms of particle size, zeta potential (Z.P), polydispersity index (PdI), and drug entrapment efficiency (E.E). Studies on compatibility were carried out with FTIR (Fourier Transform Infrared Spectroscopy) and DSC (Differential Scanning Calorimetry). Permeability, in vivo, and in vitro experiments were performed on the improved NSPs and the pure medication. After optimizing DBF-loaded β-CD NSPs, a formulation with a mean size of 158.0 ± 7.2 nm, PdI of 0.282 ± 0.0044, and E.E of 86.23 ± 2.45% was obtained, based on the assessments indicated earlier. Zeta sizer, SEM, spectrum analysis, in vitro release, and pharmacokinetic tests were among the other analyses that further validated the optimization. An area under the curve (AUC0-t) of 7.95-fold greater and a Cmax 7.356 times higher than those of the free drug was demonstrated by the optimized β-CD NSPs, which showed a notable boost. The use of DBF-loaded NSPs holds promise as an effective strategy for enhancing release and bioavailability in the treatment of melanoma.
format Article
id doaj-art-2add43ab31d140edad739aeef6db510f
institution Kabale University
issn 2175-9790
language English
publishDate 2025-01-01
publisher Universidade de São Paulo
record_format Article
series Brazilian Journal of Pharmaceutical Sciences
spelling doaj-art-2add43ab31d140edad739aeef6db510f2025-01-21T07:41:07ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902025-01-016110.1590/s2175-97902025e24209Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge FormulationKonda Sri Chaya Reddyhttps://orcid.org/0009-0004-6567-5516Darna Bhikshapathihttps://orcid.org/0000-0002-5521-2137Jaini Pavan Kumarhttps://orcid.org/0000-0001-7413-6312Abstract This research aims to create dabrafenib (DBF)-loaded nanosponges (NSPs) using β-cyclodextrin (β-CD) and diphenyl carbonate (DPC) as linker to improve oral bioavailability. DBF-loaded β-CD NSPs were synthesized by finely adjusting the molar ratio of β-CD to DPC and optimizing the stirring rate and duration using design methodology. After being loaded with DBF, the produced β-CD NSPs were characterized in terms of particle size, zeta potential (Z.P), polydispersity index (PdI), and drug entrapment efficiency (E.E). Studies on compatibility were carried out with FTIR (Fourier Transform Infrared Spectroscopy) and DSC (Differential Scanning Calorimetry). Permeability, in vivo, and in vitro experiments were performed on the improved NSPs and the pure medication. After optimizing DBF-loaded β-CD NSPs, a formulation with a mean size of 158.0 ± 7.2 nm, PdI of 0.282 ± 0.0044, and E.E of 86.23 ± 2.45% was obtained, based on the assessments indicated earlier. Zeta sizer, SEM, spectrum analysis, in vitro release, and pharmacokinetic tests were among the other analyses that further validated the optimization. An area under the curve (AUC0-t) of 7.95-fold greater and a Cmax 7.356 times higher than those of the free drug was demonstrated by the optimized β-CD NSPs, which showed a notable boost. The use of DBF-loaded NSPs holds promise as an effective strategy for enhancing release and bioavailability in the treatment of melanoma.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100322&lng=en&tlng=enBox-Behnken designCross-linkerCyclodextrinSolubilityDabrafenibDiphenyl carbonateQuality by Design
spellingShingle Konda Sri Chaya Reddy
Darna Bhikshapathi
Jaini Pavan Kumar
Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
Brazilian Journal of Pharmaceutical Sciences
Box-Behnken design
Cross-linker
Cyclodextrin
Solubility
Dabrafenib
Diphenyl carbonate
Quality by Design
title Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
title_full Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
title_fullStr Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
title_full_unstemmed Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
title_short Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
title_sort unlocking dabrafenib s potential a quality by design qbd journey to enhance permeation and oral bioavailability through nanosponge formulation
topic Box-Behnken design
Cross-linker
Cyclodextrin
Solubility
Dabrafenib
Diphenyl carbonate
Quality by Design
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100322&lng=en&tlng=en
work_keys_str_mv AT kondasrichayareddy unlockingdabrafenibspotentialaqualitybydesignqbdjourneytoenhancepermeationandoralbioavailabilitythroughnanospongeformulation
AT darnabhikshapathi unlockingdabrafenibspotentialaqualitybydesignqbdjourneytoenhancepermeationandoralbioavailabilitythroughnanospongeformulation
AT jainipavankumar unlockingdabrafenibspotentialaqualitybydesignqbdjourneytoenhancepermeationandoralbioavailabilitythroughnanospongeformulation